Sign in or Register
  • Home
    • The story of Aurigene
    • The Aurigene approach
    • Our impact
    • Media center
    • Our publications
  • About Us
    • Our journey
    • Our purpose
    • Our milestones
    • Management Team
    • Board of Directors
  • Science
    • Science
      • Our research
      • Our platform technologies
      • Our publications
    • Pipeline
      • Proprietary Pipeline
      • Partnered Programs in Clinic
  • News and Events
    • Aurigene in the media
    • News
    • Events
  • Careers
    • Life at Aurigene
    • Working at Aurigene
    • Perks at Aurigene
    • Teamwork
    • Current Openings
    • A word from Aurigeneans
  • Contact Us
Aurigene
Home
  • Home
    • The story of Aurigene
    • The Aurigene approach
    • Our impact
    • Media center
    • Our publications
  • About Us
    • Our journey
    • Our purpose
    • Our milestones
    • Management Team
    • Board of Directors
  • Science
    • Science
      • Our research
      • Our platform technologies
      • Our publications
    • Pipeline
      • Proprietary Pipeline
      • Partnered Programs in Clinic
  • News and Events
    • Aurigene in the media
    • News
    • Events
  • Careers
    • Life at Aurigene
    • Working at Aurigene
    • Perks at Aurigene
    • Teamwork
    • Current Openings
    • A word from Aurigeneans
  • Contact Us
  1. Home
  2. Publication
Targeting SWI/SNF ATPases in enhancer-addicted prostate cancer Nature 2022,434–439
December 8, 2022
by admin-aurigene

Targeting SWI/SNF ATPases in enhancer-addicted prostate cancer Nature 2022,434–439

PD-1 derived CA-170 is an oral immune checkpoint inhibitor that exhibits preclinical anti-tumor efficacy
November 9, 2022
by admin-aurigene

PD-1 derived CA-170 is an oral immune checkpoint inhibitor that exhibits preclinical anti-tumor efficacy

Small Molecule Agents Targeting PD-1 Checkpoint Pathway for Cancer Immunotherapy: Mechanisms of Action and Other Considerations for Their Advanced Development
November 9, 2022
by admin-aurigene

Small Molecule Agents Targeting PD-1 Checkpoint Pathway for Cancer Immunotherapy: Mechanisms of Action and Other Considerations for Their Advanced Development

November 15, 2022
by admin-aurigene

Safety, tolerability, pharmacokinetics and pharmacodynamics of AUR101, An RORγt inhibitor, in normal healthy volunteers

November 15, 2022
by admin-aurigene

Discovery and clinical development of the first small molecule checkpoint inhibitor for cancer therapy

November 15, 2022
by admin-aurigene

Phase 2 trial of CA-170, a novel oral small molecule dual inhibitor of immune checkpoints VISTA and PD-1, in patients (pts) with advanced solid tumor and Hodgkin…

November 15, 2022
by admin-aurigene

Phase 2 trial of CA-170, a novel oral small molecule dual inhibitor of immune checkpoints VISTA and PD-1, in patients (pts) with advanced solid tumor and Hodgkin

Home
  • Pipeline
  • Publications
  • Science
  • News and Events
  • Careers
Careers
Contact Us

Governance

Code of Business Conduct and Ethics

  • Statement of Policy
  • Link to Raise Concerns

Annual Reports

  • Link to View Report

Safety, Health, Environment and Sustainability

  • Policy Statement and Reports

Policies

CSR

  • Statement of Policy
  • Guiding Principles
  • Activities

Remuneration Policy

  • Statement of Policy

© 2022 Aurigene Discovery Technologies

Privacy & GDPR policy

Cookie policy

Crafted by: Pink Lemonade Communications Pvt. Ltd.

© 2022 Aurigene Oncology

Privacy and GDPR Policy

Cookie Policy

Apply Now